TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29317275
Drug: Dose increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose increase from 5 to 10 mg/kg based on the same criteria (DIS2 group)
Study: 29317275
Drug: Dose increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose increase to 10 mg/kg based on clinical symptoms alone (control group)
Study: 25511449
Drug: POLD technique
Normalized name: poldine
DrugBank: Poldine (DB13507)
Approvals — FDA: no, EMA: no, PMDA: no
Description: POLD technique (manual oscillatory therapy)
Study: 19141980
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (rabeprazole, amoxicillin, and furazolidone)
Study: 19141980
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (ranitidine bismuth citrate, amoxicillin, and furazolidone)
Study: 16185755
Drug: MVAC (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVAC (methotrexate 30 mg/m2 IV days 1, 15, and 22, vinblastine 3 mg/m2 IV days 2, 15, and 22, doxorubicin 30 mg/m2 IV day 2, cisplatin 70 mg/m2 day 2 of a 4-week cycle)
Study: 16185755
Drug: AC (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC (doxorubicin 30 mg/m2 + cisplatin 70 mg/m2 IV q 4 weeks)
Study: 11215835
Drug: 50/50 titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/50 titration schedule (initial dosage 50 mg/d increased in 50 mg/d increments at weekly intervals)
Study: 11215835
Drug: 100/200 titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100/200 titration schedule (initial dosage 100 mg/d increased by 100-200 mg/d at weekly intervals)
Study: 9034229
Drug: CaP/P tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaP/P tablet formulation
Study: 9034229
Drug: CaP/GG tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaP/GG tablet formulation
Study: 8515293
Drug: Piperacillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (2 g i.v. single dose)
Study: 3027841
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg daily for five days (women)
Study: 31044654
Drug: Routine medical
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medical treatment (Control Group)
Study: 25362247
Drug: Intraarticular hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular hyaluronic acid injections combined with a single local injection of corticosteroid-lidocaine (Group 2)
Study: 25362247
Drug: Intraarticular hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular hyaluronic acid injections only (Group 1)
Study: 24639149
Drug: Ferumoxytol (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol (two doses of 510 mg 5 ± 3 days apart)
Study: 24639149
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (five doses of 200 mg on five nonconsecutive days over 14 days)
Study: 23967637
Drug: Staging treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staging treatment group (acupuncture at tendon points, electric thermal needling, small needle-knife therapy, bleeding method, electric thermal therapy with thick silver needles)
Study: 12482554
Drug: DHA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (4 g/day)
Study: 12482554
Drug: EPA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (4 g/day)
Study: 8403674
Drug: Local antibiotics
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local antibiotics (Septopal) alone
Study: 8403674
Drug: Conventional antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antibiotics or combined treatment
Study: 2883060
Drug: 25 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 micrograms SMS 201-995 twice daily
Study: 31584341
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of distal radial fractures
Study: 27287207
Drug: Bevacizumab treatment
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab treatment (n = 179)
Study: 24974131
Drug: Metformin (Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (Arm B; n = 6)
Study: 24974131
Drug: Per protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per protocol analysis for Metformin (Arm B)
Study: 20549525
Drug: Interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal psychotherapy treatment for postpartum depression
Study: 20590369
Drug: Acoustic wave
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoustic wave therapy (AWT) using extracorporeal pulse activation technology (EPAT)
Study: 16324360
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with fluid resuscitation and wound management, normal saline IV drop bid for 7 days
Study: 8018759
Drug: Conventional serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional serum therapy
Study: 11739866
Drug: Dietary diacylglycerol
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary diacylglycerol (DG) oil (target dose 10 g/d) for 12 weeks
Study: 22364141
Drug: lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir (LPV/r) 400/100 mg BID + raltegravir (RAL) 400 mg BID
Study: 20163864
Drug: Bimatoprost gel
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost gel suspension applied to the base of the eyelashes every evening for 6 weeks
Study: 20163864
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline gel suspension) applied to the base of the eyelashes every evening for 6 weeks
Study: 16006724
Drug: Rosiglitazone 2
Normalized name: rosiglitazone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 2 mg/day
Study: 17203469
Drug: Eptifibatide (GP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (GP IIb/IIIa inhibitor)
Study: 6269234
Drug: Ranitidine (follow-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (follow-up after initial treatment)
Study: 6269234
Drug: Placebo (follow-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (follow-up after initial treatment)
Study: 31839104
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus cisplatin preoperative neoadjuvant chemotherapy (Group A)
Study: 31839104
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment after preoperative examination (Group B)
Study: 28711708
Drug: Ezetimibe and
Normalized name: Ezetimibe and Simvastatin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe and simvastatin combination
Study: 22447014
Drug: Combination pill
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination pill (losartan 50mg/hydrochlorothiazide 12.5mg)
Study: 22447014
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (angiotensin receptor blocker and thiazide diuretic)
Study: 17524942
Drug: MMF 500
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 500 (500 mg single oral dose)
Study: 17524942
Drug: CellCept (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CellCept (500 mg single oral dose)
Study: 11986597
Drug: Intraoperative intrapleural
Normalized name: INTRAPLEURAL MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intrapleural hypotonic cisplatin treatment (50 microg/mL in distilled water for 15 minutes)
Study: 2699994
Drug: Calcitriol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.25 to 0.5 micrograms daily)
Study: 603844
Drug: Duogastrone (carbenoxolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duogastrone (carbenoxolone sodium) 50 mg qid for 6 weeks
Study: 603844
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules qid for 6 weeks
Study: 29243795
Drug: Recombinant LH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant LH (r‐LH) added to recombinant FSH (r‐FSH) in the late follicular phase starting the same day of GnRH-antagonist administration.
Study: 17623719
Drug: 1.3 g
Normalized name: glycerin 1.3 g RECTAL SUPPOSITORY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 g of EPA + DHA daily
Study: 15154664
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with CMF regimens and radiotherapy before 90 days after surgery
Study: 15154664
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with CMF regimens and radiotherapy after 90 days after surgery
Study: 11402634
Drug: Gastric-retentive extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric-retentive extended-release metformin hydrochloride tablets
Study: 11402634
Drug: Immediate-release metformin
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release metformin hydrochloride product
Study: 8582130
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal (no drug)
Study: 2172884
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiotherapy of 30 Gy
Study: 2172884
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiotherapy of 50 Gy
Study: 2172884
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (30 Gy, 50 Gy, and chemotherapy alone)
Study: 720236
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 75 mg dipyridamol and 330 mg acetylsalicylic acid, three times daily by mouth
Study: 720236
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid alone at the same dosage
Study: 28100203
Drug: VR exposure
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR exposure treatment with diaphragmatic breathing (six cycles per minute)
Study: 28100203
Drug: VR exposure
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR exposure treatment without diaphragmatic breathing
Study: 19474138
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ferrous sulfate
Study: 17276712
Drug: Montelukast (5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5mg chewable tablet once daily for 8 weeks)
Study: 15191819
Drug: Intramuscular dissection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular dissection of perforators (DIEP flap)
Study: 10954759
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated estrogen per day
Study: 10954759
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day
Study: 9077373
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption (more than 800 g pure ethanol annually)
Study: 9077373
Drug: Low HDLc
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low HDLc (mean 0.94 mmol L‐1)
Study: 9077373
Drug: Normal HDLc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal HDLc (mean 1.25 mmol L‐1)
Study: 25262788
Drug: niosomal methylene
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: niosomal methylene blue (NMB) gel
Study: 25262788
Drug: unloaded (free)
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: unloaded (free) methylene blue (FMB) gel
Study: 9539056
Drug: Diclofenac monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac monotherapy
Study: 9539056
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with Tramadol-retard and Naproxen
Study: 2510677
Drug: APSAC (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: APSAC (30 IU) administered by intravenous bolus injection over 2 to 5 minutes
Study: 2510677
Drug: Streptokinase (SK)
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (SK) (1.5 million IU) administered by intravenous infusion over 60 minutes
Study: 803252
Drug: Adjuvant MOPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant MOPP chemotherapy with irradiation
Study: 803252
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Adjuvant MOPP chemotherapy with irradiation)
Study: 803252
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without adjuvant MOPP chemotherapy)
Study: 21762268
Drug: PBMT7 (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMT7 (pantoprazole 40 mg twice daily, metronidazole 500 mg thrice daily, bismuth subcitrate 300 mg and tetracycline 500 mg four times daily for 7 days)
Study: 21762268
Drug: PBMT14 (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMT14 (pantoprazole 40 mg twice daily, metronidazole 500 mg thrice daily, bismuth subcitrate 300 mg and tetracycline 500 mg four times daily for 14 days)
Study: 17259206
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg orally
Study: 14679326
Drug: Buffered ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Buffered ibuprofen (800 mg ibuprofen + 200 mg magnesium hydroxide)
Study: 14679326
Drug: Conventional ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional ibuprofen (800 mg ibuprofen)
Study: 11694865
Drug: Oral Disease
Normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Disease Preventive Protocol including oral physiotherapy, non-alcoholic 0.05% fluoride mouthwashes, and topical application of myconazole oral gel
Study: 11694865
Drug: Instructions on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instructions on oral physiotherapy
Study: 3134468
Drug: Tertatolol 5
Normalized name: tertatolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertatolol 5 mg with aspirin 1 g
Study: 3134468
Drug: Aspirin 1
Normalized name: aspirin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1 g
Study: 8113843
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (120 mg/m2 IV on day 1)
Study: 8113843
Drug: Moderate-dose cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose cisplatin (30 mg/m2 IV on days 2 and 3) and carboplatin (200 mg/m2 IV on day 1)
Study: 8113843
Drug: Moderate-dose cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose cisplatin and carboplatin
Study: 31155577
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (MgO) co-administration
Study: 26018671
Drug: Ketamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.25 mg/kg bolus followed by 0.25 mg/kg/h infusion)
Study: 26018671
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg bolus followed by 0.3 μg/kg/h infusion)
Study: 16309554
Drug: Transpupillary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transpupillary therapy (TTT) alone (Group A)
Study: 16309554
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide (iTA) 4 mg followed by TTT (Group B)
Study: 11093285
Drug: Insulin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (1 mU/(kg min))
Study: 8875584
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg terbutaline sulfate
Study: 8875584
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg terbutaline sulfate
Study: 29732549
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 800 mg QD
Study: 29732549
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 400 mg QD
Study: 24297950
Drug: Temsirolimus 25
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25 mg once weekly
Study: 22459771
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (1,600 μg/d)
Study: 12161519
Drug: Saline/Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline/Saline infusion
Study: 12161519
Drug: Saline/GHRH infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline/GHRH infusion
Study: 12161519
Drug: rhGH infusion
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH infusion
Study: 10334442
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (1, 10, 100, and 1,000 microg/min for 5 min each)
Study: 10334442
Drug: Benazeprilat (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazeprilat (25 microg/min) during adenosine infusion
Study: 61394
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 250 mug suspended in methyl ethyl cellulose ('Tylose') 6% solution
Study: 27324934
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration of local anaesthesia (LA)
Study: 27324934
Drug: Palatal injections
Normalized name: malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatal injections of 0.1 ml 2% lidocaine with 1:100,000 adrenaline
Study: 23292288
Drug: 10-g testosterone
Normalized name: lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-g testosterone gel daily for 6 months
Study: 20192950
Drug: 5‐HTTLPR genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HTTLPR genotype (L'L' vs S' allele) in males
Study: 20192950
Drug: 5‐HTTLPR genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HTTLPR genotype (S'S' vs L' alleles) in females
Study: 20192950
Drug: 5‐HTTLPR genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HTTLPR genotype (1 L' allele vs 2 L' alleles) in females
Study: 12760869
Drug: Indinavir 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 1,200 mg q12h
Study: 12760869
Drug: Indinavir 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 1,000 mg q8h
Study: 12760869
Drug: Efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 600 mg q24h
Study: 12760869
Drug: Efavirenz 300
Normalized name: efavirenz 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 300 mg q12h
Study: 12760869
Drug: Abacavir 300
Normalized name: abacavir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir 300 mg q12h
Study: 8334889
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg norethisterone (NET) per day
Study: 8334889
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg norethisterone (NET) per day
Study: 8334889
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg norethisterone (NET) per day
Study: 26876692
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) treatment, mean blood concentration at V1: 660 ng/ml, at V2: 1020 ng/ml, mean difference 366 units, p < 0.001
Study: 18562131
Drug: TPH1 (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPH1 (CC)
Study: 18562131
Drug: HTR1A (Reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTR1A (Reference CC)
Study: 16202353
Drug: fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl 2 mg/kg
Study: 16202353
Drug: esmolol 2
Normalized name: esmolol 20 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 2 mg/kg
Study: 10546921
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg once daily for 5 days)
Study: 1862217
Drug: Glycosaminoglycan polysulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycosaminoglycan polysulfate (600 LRU daily for 12 weeks)
Study: 30601950
Drug: Dolutegravir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir monotherapy 50 mg once daily
Study: 29691526
Drug: Black pepper-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black pepper-based beverage (BPB) preload containing 20 mg gallic acid equivalent (GAE)
Study: 26315860
Drug: Colchicine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (administered for 3 months after an initial 3 months of observation)
Study: 15498188
Drug: Spasfon (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spasfon (80 mg intravenously)
Study: 15498188
Drug: Atropine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.5 mg injected into the cervix)
Study: 11848259
Drug: Very-low-dose perindopril-indapamide
Normalized name: indapamide / perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-dose perindopril-indapamide combination